Pralatrexate, a new hope for aggressive T-cell lymphomas?

Clinical and Translational Oncology

Volumn 11, Issue 4, 2009, Pages 215-220

  Rueda, Antonio ^a   Casanova, María ^a   Quero, Cristina ^b   Medina Péez, Àngeles ^a  

^a HOSPITAL COSTA DEL SOL   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Aggressive T cell lymphomas; Pralatrexate

Indexed keywords

EDATREXATE; GEMCITABINE; METHOTREXATE; MUCIN 1; PRALATREXATE; PROTEIN BCL 2; REDUCED FOLATE CARRIER; 10-PROPARGYL-10-DEAZAAMINOPTERIN; AMINOPTERIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FOLIC ACID ANTAGONIST;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; CANCER INHIBITION; CLINICAL TRIAL; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; GENE OVEREXPRESSION; HODGKIN DISEASE; HUMAN; IC 50; LEUKOPENIA; LUNG INFILTRATE; MACULOPAPULAR RASH; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; VITAMIN SUPPLEMENTATION; VOMITING; ANIMAL;

AMINOPTERIN; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FOLIC ACID ANTAGONISTS; HUMANS; LYMPHOMA, T-CELL;

EID: 67650240123     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0343-9     Document Type: Review

References (31)

1. Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392
2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon
3. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. Blood 89:3909-3918
4. Anderson JR, Armitage JO, Weisenburger DD et al (1998) Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Ann Oncol 9:717-720
5. International T-Cell Lymphoma Project (2008) International peripheral T-cell and natural killer/Tcell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130
6. Coiffier B, Brousse N, Peuchmaur M et al (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomaes Aggressives). Ann Oncol 1:45-50
7. Evens AM, Gartenshaus RB (2004) Treatment of T-cell Non-Hodgkin's lymphoma. Curr Treat Opt Oncol 5:289-303
8. Lopez-Guillermo A, Cid J, Salar A et al (1998) Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9:849-855
9. Rudiger T, Weisenburger DD, Anderson JR et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13:140-149
10. Campo E, Gaulard P, Zucca E et al (1998) Report of the European Task Force on Lymphomas: Workshop on peripheral T-cell lymphomas. Ann Oncol 9:835-843
11. Molina JR (2008) Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 11:508-521
12. Gangjee A, Jain HD, Kurup S (2008) Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II. Anticancer Agents Med Chem 8:205-231
13. Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26:153-181
14. Dhaliwal HS, Rohatiner AZ, Gregory W et al (1993) Combination chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma. Br J Cancer 68:767-774
15. Patte C (2002) Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Hematol 15:695-711
16. Fotoohi AK, Albertioni F (2008) Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma 49:410-426
17. Sirotnak FM, DeGraw JI, Moccio DM et al (1984) New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12:18-25
18. Gralla RJ (1995) Edatrexate studies in non-small cell lung cancer. Lung Cancer 12[Suppl 1]:S187-191
19. DeGraw JI, Colwell WT, Piper JR et al (1993) Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 36:2228-2231
20. Sirotnak FM, DeGraw JI, Colwell WT et al (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42:313-318
21. Wang ES, O'Connor O, She Y et al (2003) Activity of a novel antifolate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44:1027-1035
22. O'Connor OA (2006) Pralatrexate: An emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 18:591-597
23. Toner LE, Vrhovac R, Smith EA et al (2006) The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 12:924-932
24. Cadman E, Eiferman F (1979) Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: Study of L1210 and human leukemic cells. J Clin Invest 64:788-797
25. Krug LM, Ng KK, Kris MG et al (2000) Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 6:3493-3498
26. Mould DR, Sweeney K, Duffull S et al (2007) A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 110:1370
27. O'Connor O, Hamlin P, Neylon E et al (2006) Early-phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies. Eur J Cancer 4[Suppl 12]:aBstract 461
28. O'Connor, Hamlin PA, Portlock C et al (2007) Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139:425-428
29. Leitenberger JJ, Berthelot CN, Polder KD et al (2008) CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 58:480-484
30. O'Connor OA, Pro B, Pinter-Brown L et al (2008) PROPEL: A multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma. Blood (ASH Annual Meeting Abstracts 2008) 112:ABstract 261
31. Horwitz SM, Vose JM, Advani R et al (2008) A phase 1/2A open-label study of pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies. Blood (ASH Annual Meeting Abstracts 2008) 112:ABstract 1570